

Health Technology Assessment Policy and Methods Review

Workplan

HTA Review key activities:

A commitment under the Strategic Agreement

In the 2022-2027 Strategic Agreement between the Commonwealth and Medicines Australia (Strategic Agreement) the Commonwealth agreed to support and resource a HTA Policy and Methods Review (the Review), including establishing a Reference Committee (Committee).

The key activities set out in this workplan are reflective of clause 5.3 and 5.4 of the Strategic Agreement:

- Prepare the **Terms of Reference (ToR)** for the HTA Review, in consultation with stakeholders
- Engage an expert in HTA to undertake an **analysis** of current methods used by the PBAC, contemporary **research** and relevant methodologies and purchasing practices used by comparable jurisdictions guided by the Terms of Reference
- Conduct public **consultations** to inform the Review
- The Reference Committee to prepare and agree final **report and recommendations** to the PBAC and the Commonwealth.

Who are the Reference Committee?

Member	Role on the Committee
Adjunct Professor Debora Picone AO	Independent Chair
Ms Ann Single	Patient Representative
Dr Dawn Casey PSM	Patient Representative
Professor Andrew Wilson	Chair of the PBAC
Professor Andrew Roberts AM	Clinical/Scientific Representative
Ms Elizabeth de Somer	Member nominated by Medicines Australia
Ms Adriana Platona PSM	Government Nominee

Subscribe to PBS news at www.pbs.gov.au to receive notifications of additional details throughout the Review.

Overview of the Review process



Overview of key activities

Terms of Reference

The HTA Review ToR finalised 13 February 2023 following feedback from patients, consumers, industry, advisory bodies and Commonwealth and state and territory governments and published on the HTA Review website on 22 March 2023.

Consultation

Three consultation stages including two rounds of extensive public consultation, and ongoing deep-dives. For more information download the consultation plan on the HTA Review website.

Research and Analysis

Expert in HTA contracted to undertake research and analysis (R & A) in addition to material prepared by the department on relevant topics to inform the Review. These initial analyses will be published to facilitate workshop of options in Consultation 2.

Topics will include:

- Consumer engagement and consideration in HTA
- Emerging health technologies and characteristics that may challenge existing Australian funding structures and/or health technology assessment approaches
- Australian and international Health technology market approval, funding, and assessment pathways and timelines including special pathways and equity considerations
- Early identification of emerging technologies and early value assessment
- HTA Methods: Determination of Population Intervention Comparator Outcome (PICO), Clinical Evaluation, Economic evaluation
- Funding and purchasing decisions and Managing Uncertainty
- Health technology utilisation and outcome data monitoring and reporting

Report and recommendations

Following Consultation 1 and initial findings from research and analysis, the Committee will develop draft options which will be workshopped in Consultation 2.

Final recommendations will be informed by stakeholder consultations, deep-dives, HTA expert analysis, Departmental and intra-governmental inputs, and conferences.